CA2094259A1 - Fragments therapeutiques du facteur de von willebrand - Google Patents

Fragments therapeutiques du facteur de von willebrand

Info

Publication number
CA2094259A1
CA2094259A1 CA002094259A CA2094259A CA2094259A1 CA 2094259 A1 CA2094259 A1 CA 2094259A1 CA 002094259 A CA002094259 A CA 002094259A CA 2094259 A CA2094259 A CA 2094259A CA 2094259 A1 CA2094259 A1 CA 2094259A1
Authority
CA
Canada
Prior art keywords
polypeptide
fragment
sequence
residue
von willebrand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002094259A
Other languages
English (en)
Inventor
Zaverio M. Ruggeri
Jerry L. Ware
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2094259A1 publication Critical patent/CA2094259A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002094259A 1990-10-17 1991-10-17 Fragments therapeutiques du facteur de von willebrand Abandoned CA2094259A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US600,183 1984-04-13
US60018390A 1990-10-17 1990-10-17
US61300490A 1990-11-13 1990-11-13
US613,004 1990-11-13
US67552991A 1991-03-27 1991-03-27
US675,529 1991-03-27
PCT/US1991/007756 WO1992006999A1 (fr) 1990-10-17 1991-10-17 Fragments therapeutiques du factor de von willebrand

Publications (1)

Publication Number Publication Date
CA2094259A1 true CA2094259A1 (fr) 1992-04-18

Family

ID=27416797

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002094259A Abandoned CA2094259A1 (fr) 1990-10-17 1991-10-17 Fragments therapeutiques du facteur de von willebrand

Country Status (4)

Country Link
JP (1) JPH06502541A (fr)
AU (1) AU9069591A (fr)
CA (1) CA2094259A1 (fr)
WO (1) WO1992006999A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686901A1 (fr) * 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
IL109383A0 (en) * 1993-04-23 1994-07-31 Bio Technology General Corp Method for enhancing thrombolysis
AU1382595A (en) * 1994-01-07 1995-08-01 Novo Nordisk A/S Factor viii derivatives
JP2021519280A (ja) * 2018-03-21 2021-08-10 バクスアルタ インコーポレイテッド クロマトグラフィー法によるｖｗｆとｖｗｆプロペプチドの分離

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors

Also Published As

Publication number Publication date
WO1992006999A1 (fr) 1992-04-30
AU9069591A (en) 1992-05-20
JPH06502541A (ja) 1994-03-24

Similar Documents

Publication Publication Date Title
JP2525438B2 (ja) ファクタ―８：ｃの製造方法
JP2515468B2 (ja) ヒト抗トロンビンｉｉｉ
EP0315683B1 (fr) Sequences adn, molecules adn recombinant, et procedes de production de l'antigene-3 associe a la fonction lymphocyte
EP0502892B1 (fr) RECEPTEUR C3b/C4b HUMAIN (CR1)
FI104260B (fi) Biologisesti aktiivista yhdistelmä-DNA-ihmisentekij-VIII-johdannaista koodittava DNA, tämän sisältävä yhdistelmä-DNA-ilmentämisvektori ja isäntäsolu sekä menetelmä biologisesti aktiivisen yhdistelmä-DNA-ihmisentekijä-VIII-johdannaisen valmistamiseksi
US5340727A (en) GPIbα fragments and recombinant DNA expression vectors
EP0775711B1 (fr) Peptide a action inhibant l'agregation plaquettaire et procede de production de ce compose
AU643306B2 (en) Anticoagulant polypeptides
EP0627923B1 (fr) Domaines therapeutiques du facteur von willebrand
JPH02121934A (ja) 組合せ医薬組成物
EP0641215A1 (fr) Analogues de thrombomoduline resistant a la protease
EP0517826A1 (fr) CLONAGE ET PRODUCTION DE POLYPEPTIDES HUMAINS DE DOMAINE DE LIAISON DE GPIb DE FACTEUR DE VON WILLEBRAND ET LEURS PROCEDES D'UTILISATION
EP0458903A1 (fr) Analogues solubles de la thrombomoduline
CA2094259A1 (fr) Fragments therapeutiques du facteur de von willebrand
WO1993000357A1 (fr) Polypeptides therapeutiques bases sur le facteur de von villebrand
CA2235628A1 (fr) Facteur viii hybride possedant une activite modifiee
WO1992017192A1 (fr) Fragments therapeutiques du facteur willebrand
WO1993011778A1 (fr) Molecules anti-thrombotiques bifonctionnelles et polypetptides anti-trhombotiques
AU645077C (en) Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same

Legal Events

Date Code Title Description
FZDE Dead